We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LZMH:NASDAQLZ Technology Holdings Limited Analysis

Data as of 2026-06-08 - not real-time

$1.59

Latest Price

9/10Risk

Risk Level: High

Executive Summary

LZ Technology Holdings (LZMH) is trading around $1.59, far below its 52‑week high of $543 and well under the DCF‑derived fair value of roughly $17.7, indicating a massive discount. The stock is caught in a bearish trend, with the 20‑day SMA sitting well above the current price and the 50‑day and 200‑day SMAs even higher, reinforcing downside pressure. Technical momentum is mixed: the MACD histogram turned positive, suggesting a short‑term bullish signal, yet the RSI hovers near the 30‑point oversold threshold, reflecting weak buying interest. Volume has been increasing, but the market‑cap of only $14 million and daily volume of under 8 million shares point to thin liquidity. Recent corporate action—a 1‑for‑20 reverse share split—adds a layer of short‑term uncertainty as the price may adjust sharply. Meanwhile, the company’s financial health is fragile, with negative operating cash flow, a gross margin of just 3 %, and a debt‑to‑equity ratio exceeding 100 %.
Fundamentally, the firm reports a steep revenue growth rate of 91 % but still posts negative operating and net margins, and its free cash flow is modest relative to debt obligations, raising concerns about sustainability. The beta of –1.76 and a 30‑day volatility above 180 % underscore extreme price swings that can amplify both gains and losses. Regulatory and geographic exposure to China’s technology sector introduces heightened policy risk, while the lack of any dividend history eliminates income‑yield considerations. Given the combination of deep discount, distressed fundamentals, and pronounced risk factors, the stock may appeal only to highly risk‑tolerant investors seeking speculative upside. The reverse split may improve share price perception but does not resolve balance‑sheet constraints. Consequently, a prudent stance would be to limit exposure until clearer turnaround signals emerge.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • bearish technical trend with price below key moving averages
  • negative operating cash flow and high debt load
  • extreme volatility and inverse beta amplifying downside risk

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • substantial discount to DCF fair value
  • potential liquidity improvement from reverse split
  • ongoing earnings losses and balance‑sheet weakness

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • possible upside if turnaround strategy succeeds
  • high exposure to Chinese regulatory environment
  • persistent cash‑flow and profitability challenges

Key Metrics & Analysis

Financial Health

Revenue Growth91.20%
Profit Margin-15.37%
ROE-277.51%
ROA-31.62%
Debt/Equity108.83
P/B Ratio1.8
Op. Cash Flow$-41201000
Free Cash Flow$5.5M
Industry P/E33.4

Technical Analysis

TrendBearish
RSI30.0
Support$1.03
Resistance$3.20
MA 20$1.44
MA 50$9.04
MA 200$36.69
MACDBullish
VolumeIncreasing
Fear & Greed Index88.61

Valuation

Fair Value$17.69
GradeUndervalued
TypeValue

Risk Assessment

Beta-1.76
Volatility182.32%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.